Hims & Hers Announces Strategic Shift in US Weight Loss Business with Novo Nordisk Collaboration

Key Points from the Report

• Strategic Collaboration: Hims & Hers Health, Inc. (NYSE: HIMS) has entered a new collaboration with Novo Nordisk, marking a significant shift in its US weight loss business strategy.
• Alignment of US and Global Strategies: The company is aligning its US offerings with its global approach, focusing on providing access to a broader variety of FDA-approved GLP-1 medications for weight loss.
• Transition from Compounded Medications: Hims & Hers will stop advertising compounded GLP-1 offerings, instead prioritizing FDA-approved medications. Existing patients will be transitioned to FDA-approved drugs when clinically appropriate.
• Limited Compounded Offerings: Access to compounded GLP-1s (such as semaglutide) will be available only for a limited subset of customers whose clinical needs cannot be met by available FDA-approved options, and only if determined necessary by their healthcare provider.
• Expanded Product Access: The agreement with Novo Nordisk will bring Ozempic® (semaglutide) injections (0.5 mg, 1 mg, 2 mg), Wegovy® (semaglutide) pills and injections (including 1.7 mg, 2.4 mg injections and 1.5 mg, 4 mg, 9 mg, 25 mg tablets) to the platform later this month.
• Education and Transition: Hims & Hers will actively educate US customers about their expanded options for FDA-approved treatments and facilitate seamless transitions where appropriate.
• Future Collaboration: The company and Novo Nordisk plan to collaborate further, potentially bringing additional products to market as they become available.
• Comprehensive Support Services: Hims & Hers will continue offering support services such as direct provider access, personalized nutrition guidance, and ongoing clinical check-ins alongside its treatment offerings.
• Lawsuit Dismissal: Novo Nordisk is dismissing its lawsuit against Hims & Hers without prejudice, removing a potential legal overhang.

Important Shareholder Information & Potential Price Sensitivity

• Market Position: By aligning US and global models and expanding access to FDA-approved GLP-1 medications, Hims & Hers aims to become the largest global consumer health platform for affordable, approved weight loss medications. This strategic move could significantly enhance the company’s market share and competitive position.
• Revenue Impact: The transition away from compounded GLP-1s to branded, FDA-approved drugs may drive increased customer demand, particularly as industry progress has made these treatments more affordable and flexible. If successful, this could positively impact future revenue and earnings.
• Legal Risk Removed: The dismissal of Novo Nordisk’s lawsuit without prejudice clears a legal uncertainty that could have affected investor sentiment and share price.
• Risks & Uncertainties: The company notes several risks, including customer response to the transition, timing and logistics of updating platform offerings, potential future collaborations, risks related to international expansion, regulatory changes, and the unpredictable impact any partnership or business shift may have on future financial results.
• Forward-Looking Statements: Actual results may differ materially from expectations due to numerous factors. The company does not commit to updating these statements unless required by law.

Detailed Analysis

Hims & Hers Health, Inc. has announced a pivotal change in its US weight loss business strategy through a new collaboration with Novo Nordisk. This move is designed to align its US operations with its global strategy, focusing on providing customers access to a wide range of FDA-approved GLP-1 medications, including both injectable and oral forms of semaglutide (Ozempic®, Wegovy®). The company’s platform will now feature these branded medications at more affordable prices, responding to increased customer demand for approved and branded options.

As part of this transition, Hims & Hers will discontinue marketing and advertising compounded GLP-1 treatments, shifting its focus entirely to FDA-approved products. Existing patients using compounded medications will be given the opportunity to transition to FDA-approved drugs, with compounded GLP-1s remaining available on a limited basis for customers with unique clinical needs, subject to provider determination.

The collaboration with Novo Nordisk will facilitate the introduction of multiple dosage options for Ozempic® and Wegovy® on the Hims & Hers platform later this month. The platform will also be enhanced with educational initiatives to inform customers about their expanded treatment choices and to support smooth transitions to FDA-approved medications. The companies intend to further collaborate in the future, potentially adding new innovative products to the platform as they become available.

Importantly, Hims & Hers will continue to provide comprehensive support services, including access to healthcare providers, personalized nutrition guidance, and regular clinical check-ins, reinforcing its commitment to holistic care.

Another notable development is the dismissal of Novo Nordisk’s lawsuit against Hims & Hers without prejudice, eliminating a legal risk and uncertainty for the company.

From an investor perspective, these strategic changes aim to position Hims & Hers as a leader in consumer health platforms for weight loss, potentially driving increased revenue and market share. However, the company highlights several risks and uncertainties, including the logistics of updating platform offerings, customer acceptance, regulatory changes, and the unpredictable impact of the partnership and business shift on future financial results.

Conclusion

This announcement marks a significant inflection point for Hims & Hers, potentially affecting its future growth trajectory, revenue streams, and investor sentiment. The alignment with Novo Nordisk and expanded access to FDA-approved medications, combined with the removal of legal risk, could be price sensitive and impactful for shareholders.

Disclaimer

This article contains forward-looking statements based on management’s current expectations, assumptions, and beliefs regarding future developments. Actual results may differ materially due to numerous risks and uncertainties, including those detailed above. This article is for informational purposes only and does not constitute investment advice. Investors should review all relevant filings and consult their financial advisors before making any investment decisions.

View Hims & Hers Health, Inc. Historical chart here